Pictorial Representation of Illness and Self Measure
PRISM
1 other identifier
observational
220
1 country
1
Brief Summary
PRISM (Pictorial Representation of Illness and Self Measure) has been developed since the mid-1990s; the task was first developed as a simple measure of how a person was coping with his or her experience of illness. This is an international, multicentre study to evaluate the PRISM tool for the assessment of suffering in rheumatoid arthritis at different stages of the illness and the effect of treatment intervention. There are 5 sites: Berlin, Oxford, Limoges, Montreal and Queensland. The study will recruit 200 patients in total. In addition to the procedures for the patient's routine clinical visit, the patients will be invited to answer a series of questionnaires and donate 20ml blood sample. Patients will be asked to attend 3 times over 24 weeks
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 11, 2012
CompletedFirst Posted
Study publicly available on registry
October 16, 2012
CompletedStudy Start
First participant enrolled
October 18, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2018
CompletedApril 30, 2019
October 1, 2017
4.7 years
October 11, 2012
April 29, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
PRISM/PRISM+
Questionnaires
30 September 2015
Study Arms (4)
Group 1A
Early phase, requiring change in treatment
Group 2
Established phase, stable treatment
Group 2A
Established phase, requiring a change in treatment
Group 1
Early phase, stable treatment
Eligibility Criteria
Patients with rheumatoid arthritis from hospital clinics
You may qualify if:
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- Written confirmed diagnosed of rheumatoid arthritis
You may not qualify if:
- A diagnosis of any of the following:
- Multiple sclerosis
- Motor neurone disease
- Parkinson's disease
- Alzheimer's disease
- Depression or anxiety disorders as identified using the Patient depression screening questions from the patient health questionnaire 9 (PHQ9).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Oxfordlead
- UCB Pharmacollaborator
Study Sites (1)
Nuffield Orthopaedic Centre
Oxford, OX3 7HE, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peter Taylor, FRCP, PhD
University of Oxford
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 11, 2012
First Posted
October 16, 2012
Study Start
October 18, 2012
Primary Completion
June 30, 2017
Study Completion
June 30, 2018
Last Updated
April 30, 2019
Record last verified: 2017-10